These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10199158)

  • 41. Self-association of long-acting insulin analogues studied by size exclusion chromatography coupled to multi-angle light scattering.
    Jensen MH; Wahlund PO; Jacobsen JK; Vestergaard B; van de Weert M; Havelund S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Oct; 879(28):2945-51. PubMed ID: 21937288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with insulin analogues in children.
    Danne T; Deiss D; Hopfenmüller W; von Schütz W; Kordonouri O
    Horm Res; 2002; 57 Suppl 1():46-53. PubMed ID: 11979022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents.
    Bristow AF
    Trends Biotechnol; 1993 Jul; 11(7):301-5. PubMed ID: 7763953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design of insulin analogues for meal-related therapy.
    Brange J
    J Diabetes Complications; 1993; 7(2):106-12. PubMed ID: 8518452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probing the correlation between insulin activity and structural stability through introduction of the rigid A6-A11 bond.
    Ong SC; Belgi A; van Lierop B; Delaine C; Andrikopoulos S; MacRaild CA; Norton RS; Haworth NL; Robinson AJ; Forbes BE
    J Biol Chem; 2018 Jul; 293(30):11928-11943. PubMed ID: 29899115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preparation of a microcrystalline suspension formulation of Lys(B28)Pro(B29)-human insulin with ultralente properties.
    Richards JP; Stickelmeyer MP; Frank BH; Pye S; Barbeau M; Radziuk J; Smith GD; DeFelippis MR
    J Pharm Sci; 1999 Sep; 88(9):861-7. PubMed ID: 10479347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant human insulin analogues: recommendations for optimal use.
    Torlone E
    BioDrugs; 1998 May; 9(5):363-74. PubMed ID: 18020571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altering the association properties of insulin by amino acid replacement.
    Brems DN; Alter LA; Beckage MJ; Chance RE; DiMarchi RD; Green LK; Long HB; Pekar AH; Shields JE; Frank BH
    Protein Eng; 1992 Sep; 5(6):527-33. PubMed ID: 1438163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I.
    DiMarchi RD; Chance RE; Long HB; Shields JE; Slieker LJ
    Horm Res; 1994; 41 Suppl 2():93-6. PubMed ID: 8088710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin lispro: a new quick-acting insulin analogue.
    Gale EA
    Expert Opin Investig Drugs; 1997 Sep; 6(9):1247-56. PubMed ID: 15991899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Self-association properties of monomeric insulin analogs under formulation conditions.
    Richards JP; Stickelmeyer MP; Flora DB; Chance RE; Frank BH; DeFelippis MR
    Pharm Res; 1998 Sep; 15(9):1434-41. PubMed ID: 9755897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues.
    Maikawa CL; Smith AAA; Zou L; Meis CM; Mann JL; Webber MJ; Appel EA
    Adv Ther (Weinh); 2020 Jan; 3(1):. PubMed ID: 32190729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histopathological nerve and skeletal muscle changes in rats subjected to persistent insulin-induced hypoglycemia.
    Jensen VF; Mølck AM; Heydenreich A; Jensen KJ; Bertelsen LO; Alifrangis L; Andersen L; Søeborg H; Chapman M; Lykkesfeldt J; Bøgh IB
    J Toxicol Pathol; 2016 Jan; 29(1):17-30. PubMed ID: 26989298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control.
    Trautmann ME
    Horm Metab Res; 1994 Dec; 26(12):588-90. PubMed ID: 7705764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Insulin therapy].
    Brunetti P
    Minerva Endocrinol; 2001 Jun; 26(2):65-86. PubMed ID: 11479436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Rapid-acting insulin analogues].
    Matsuda A; Kuzuya T
    Nihon Rinsho; 1999 Mar; 57(3):709-18. PubMed ID: 10199158
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.